Takeda Oncology: Difference between revisions

Content deleted Content added

Inline

Revision as of 15:09, 6 March 2008

Millennium Pharmaceuticals Nasdaq: MLNM is a biotechnology company based in the Cambridge, Massachusetts area of the United States of America. It was founded in 1993. Millennium's research, development and commercialization activities are focused on oncology and inflammation. In these fields the company markets Velcade, a cancer product, and Integrilin for actute coronory syndrome. It is also developing other product candidates. It was one of the first companies to systematically search for genes linked to disease, but none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research.^[1]

References

^ "Shift Seen Atop Millennium Pharmaceuticals". New York Times. 2005-06-29. Retrieved 2008-02-23.

External links

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

[1] "Shift Seen Atop Millennium Pharmaceuticals". New York Times. 2005-06-29. Retrieved 2008-02-23.

[1]

@@ Line 1: / Line 1: @@
+'''Millennium Pharmaceuticals''' {{nasdaq|MLNM}} is a [[biotechnology]] company based in the [[Cambridge, Massachusetts]] area of the [[United States of America]]. It was founded in 1993.
-{{Infobox Company |
+Millennium's research, development and commercialization activities are focused on oncology and inflammation. In these fields the company markets [[Velcade]], a cancer product, and [[Integrilin]] for actute coronory syndrome. It is also developing other product candidates. It was one of the first companies to systematically search for genes linked to disease, but none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research.<ref>{{cite news |title=Shift Seen Atop Millennium Pharmaceuticals |url=http://www.nytimes.com/2005/06/29/business/29drug.html |work=[[New York Times]] |date=2005-06-29 |accessdate=2008-02-23 }}</ref>
-| company_name = Millennium Pharmaceuticals, Inc.
-| company_logo = [[Image:Millennium_Logo.gif|210px]]
-| company_type = [[Public company|Public]] (NYSE:[http://quotes.nasdaq.com/asp/summaryquote.asp?symbol=MLNM%60&selected=MLNM%60 MLNM])
-| company_slogan = Breakthrough Science. Breakthrough Medicine.®|
-| foundation = [[1993]]
-| location = [[Cambridge, MA]], [[USA]]
-| key_people = Deborah Dunsire, M.D., President & CEO<br/>
-| industry = [[Biotechnology]], [[Pharmaceutical Company]]
-| products = VELCADE® ([[bortezomib]]) for injection
-| num_employees = 965 (approx.)
-| homepage = http://www.millennium.com/
-}}
-[[Image:40_landsdowne.jpg|thumb|right|275px|Millennium Pharmaceuticals' corporate headquarters located at 40 Landsdowne Street, Cambridge, Massachusetts]]
-'''Millennium Pharmaceuticals, Inc.''' {{nasdaq|MLNM}} is a leading biopharmaceutical company based in [[Cambridge]], [[Massachusetts]]. The Company markets VELCADE® ([[bortezomib]]) for Injection, a novel [[cancer]] product, and has a robust clinical development [[pipeline]] of product candidates. Millennium [[research]], development and commercialization activities are focused in two [[therapeutic]] areas: [[oncology]] and [[inflammation]]. By applying its knowledge of the human [[genome]], understanding of [[disease]] mechanisms and [[industrialized]] drug discovery platform, Millennium is developing a diverse pipeline of innovative product candidates.
-== History ==
+==References==
-Millennium was founded in [[1993]] with a [[vision]] that still drives the company to this day. Millennium believes that by applying the methods of leading [[science]] to the art of [[drug]] discovery, it will develop breakthrough products that will fundamentally change the practice of [[medicine]].
-In its early years, Millennium focused on building top-notch science and business teams to help achieve this vision. Attracted by scientific [[leadership]], entrepreneurial spirit, and aggressive but judicious growth, Millennium quickly began to earn the attention and respect of many [[scientists]], business people and [[journalists]] from around the world.<ref>{{cite web|accessdate=2008-03-05|url=http://news.google.com/news?hl=en&tab=wn&ned=us&q=millennium+pharmaceutical|title=Millennium Pharmaceuticals News |publisher=Google News}}</ref>
-Beginning in 1994, Millennium created more than 20 strategic alliances with leading pharmaceutical and biotechnology companies. These alliances provided Millennium with close to $2 billion of committed funding that was used to develop and enhance its pipeline. With an innovative, integrated science and [[technology]] platform, expertise in drug-target discovery, and industry-leading partnerships, the company was geared to prime the product pipeline.
-At that time, Millennium leadership noted that discovering new drug targets was only one step in the pathway toward the ultimate goal of providing breakthrough therapeutic products that would help patients. Through transformational mergers and acquisitions, Millennium continued to advance toward the goal of building a leading biopharmaceutical company. A merger with Leukosite in 1999 brought the company its first drug close to market, [[Campath]]®  (alemtuzumab) Injection, and additional investigational drugs in clinical trials.  In 2000, a merger with Cambridge Discovery [[Chemistry]] gave Millennium a strong presence in the [[United Kingdom]] and added to the organization more than 100 scientists with expertise in chemistry. In a strategic business decision, Campath was later sold to the Millennium partner for the drug, ILEX Oncology, which in turn was acquired by [[Genzyme]].
-In February 2002, a merger with COR Therapeutics — among the largest such mergers in the history of the biotech industry at that time — helped to further solidify the Company’s standing as a leading biopharmaceutical company. In addition to creating a strong pipeline of novel therapeutics, the merger added cardiovascular research and drug development to the Company's other key therapeutic areas: oncology and inflammation. The merger also brought INTEGRILIN® ([[eptifibatide]]) Injection, a market-leading intravenous anti-[[platelet]] drug for patients with severe [[cardiovascular diseases]], into the Millennium fold. Millennium partnered with [[Schering-Plough]] on the development and marketing of INTEGRILIN until 2005 when Millennium licensed the exclusive U.S. commercialization and development rights of INTEGRILIN to Schering-Plough.
-As Millennium celebrated its tenth [[anniversary]] in 2003, the Company reached new heights. VELCADE was launched in May of that year for the treatment of relapsed and refractory [[multiple myeloma]] – a cancer of the blood. VELCADE is now approved in the U.S. for treatment of multiple myeloma patients after one prior therapy. VELCADE — the first U.S. Food and Drug Administration ([[FDA]]) approved [[proteasome]] inhibitor — reached the market in record time and represented the first treatment in more than a decade to be approved for patients with multiple myeloma.
-In late [[December]] [[2007]], Millennium successfully submitted a supplemental new drug application ([[sNDA]]) to the FDA for VELCADE for previously untreated multiple myeloma. The sNDA submitted to the FDA for this indication included data from the Phase III VISTA.<ref>{{cite web|accessdate=2008-03-05|url=http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1052541&highlight=|title=VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with [[melphalan]] and [[prednisone]] |publisher=Millennium Corporate Communications }}</ref> study, a large, well-controlled [[international]] clinical trial, comparing a VELCADE based regimen to a traditional standard of care. Priority review was granted by the FDA in [[January]] [[2008]].
-== Products ==
-{| class="wikitable" style="text-align:center";
-|+ Product Portfolio
-|-valign="bottom"
-! width="10%"|Brand Name
-! width="12%"|Drug Name(s)
-! width="45%"|Indication
-! width="10%"|Date Approved (USA)<ref>{{cite web|accessdate=2008-03-05|url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/|title=FDA Approves VELCADE |publisher=FDA }}</ref>
-! width="35%"|Partner
-|-valign="top"
-|'''VELCADE®'''
-|bortezomib
-|VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least 1 prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.
-|05-13-2003
-|Ortho Biotech and [[Janssen-Cilag]], members of the [[Johnson & Johnson]] Family of Companies, are responsible for commercialization of VELCADE in Europe and the rest of the world.
-|}
-[[Image:Velcade_Shot.jpg|thumb|left|225px|VELCADE (bortezomib)]]
-VELCADE is the first oncology drug marketed and promoted by Millennium. The rapid clinical development of VELCADE—with FDA approval granted little more than four and a half years after initiation of the first clinical trial—reflects its intense commitment to novel treatments for cancer patients. To discover and develop such treatments, the Company focuses on key molecular pathways that play crucial roles in underlying disease processes, and on identifying therapeutically significant differences that may exist among [[people]].  Millennium applies this approach broadly throughout its R&D program to develop novel treatments not just for cancer but also for a number of other important diseases.
-VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and [[Johnson & Johnson]] Pharmaceutical Research & Development, L.L.C. Millennium is responsible for [[commercialization]] of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. [[Janssen]] Pharmaceutical K.K. is responsible for commercialization in [[Japan]]. For a limited period of time, Millennium and Ortho Biotech Inc. are co- promoting VELCADE in the U.S. Approved in 85 countries, at least 85,000 patients have been treated with VELCADE globally.
-== References ==
 {{reflist}}
 ==External links==
-*[http://www.millennium.com Official website]
+*[http://www.millennium.com Millennium Pharmaceuticals]
-*[http://www.mlnm.com Official website #2]
+*[http://www.millennium.com/about/history/index.asp Company History]
-*[http://www.velcade.com VELCADE website]
-*[http://www.upfronttrial.com VELCADE UPFRONT Trial website]
 [[Category:Companies in the NASDAQ Biotechnology Index]]